Organ-sparing treatment of advanced bladder cancer: First experience with paclitaxel as alternative to cisplatin

Diestelhorst, Andrea; Mueller, Andreas S.; Kuehn, R.; Fornara, P.; Kuhnt, Thomas; Dunst, J

doi:10.1016/s0360-3016(04)01637-2

Search citation statements

Order By: Relevance

Paper Sections

Select...

Discussion1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2014

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a poor-risk patient population, paclitaxel was used twice weekly with concomitant RT. All evaluable patients achieved a CR with a 3-year OS of 40% ( 56 ). In a phase I–II trial (RTOG 0524), non-surgical elderly patients received paclitaxel (41 patients) with or without transtuzumab (21 patients overexpressing HER2/Neu).…”

Section: Discussionmentioning

confidence: 99%

Trimodality Therapy for Bladder Preservation in the Elderly Population with Invasive Bladder Cancer

Turgeon

Souhami

2014

Front. Oncol.

View full text Add to dashboard Cite

Bladder cancer is considered as primarily a disease of the elderly, typically aged in their 70s or 80s and often with associated medical comorbidities. Unfortunately, fewer elderly patients receive radical treatment for muscle-invasive bladder cancer (MIBC) that their younger counterparts. Over the last decades, several studies have shown that the use of trimodality therapy consisting of transurethral bladder resection followed by concomitant chemotherapy and radiation therapy results in comparable outcomes to radical cystectomy, considered the gold standard for this disease. In this review, we revised the literature on bladder-preservation treatments using the trimodality approach in the elderly population with MIBC.

show abstract

Section: Discussionmentioning

confidence: 99%